Clinical Trial

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Study acronym: MERIT-lung
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 months.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-05-25; most recent amendment 2026-04-29.
Trial Details
NCT Number NCT05398094
Lead Sponsor Fundación GECP
Conditions Non-small Cell Lung Cancer Stage III, KRAS P.G12C
Enrollment 19 participants
Start Date 2022-03-21
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30